HeartFlow touts registry study, large hospital trial data

HeartFlow this week released data from two studies of its HeartFlow fractional flow reserve FFRct analysis system, touting that the system allows for the more effective differentiation of patients who need coronary stenting or bypass surgery and those who can be managed on medications alone. HeartFlow’s FFRct technology works by taking the data from a standard CT scan and applying algorithms that result in a color-coded 3D “map” detailing the changes in flow across coronary lesions. Results from the Advance registry study were published in the European Heart Journal and results from the Aarhus University Hospital experience were published in Journal of the American College of Cardiology, and both were presented during the European Society of Cardiology Conference, HeartFlow said. Redwood City, Calif.-based HeartFlow said that in both studies, the HeartFlow analysis allowed for more efficient separation of patients who required invasive management and those who did not through the identification of patients at very low risk of adverse events under medical therapy, and those whose risk was reduced by invasive management. The Advance registry included data from more than 5,000 patients in the US, Japan, Europe and Canada, while the Aarhus University Hospital experience included data from 3,600 patients in Denmark followed for an average of two years, HeartFlow said. Results from the Advance registry showed that the use of the HeartFlow analysis resulted in recons...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials HeartFlow Source Type: news